Drug
Dacogen
Dacogen is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
completed133%
terminated267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT03306264
terminatedphase_1
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage
NCT04252248
terminatedphase_2
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
NCT00630994
Clinical Trials (3)
Showing 3 of 3 trials
NCT03306264Phase 3
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT04252248Phase 1
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage
NCT00630994Phase 2
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3